Terminated PHASE2 INTERVENTIONAL 4-arm NCT00760929

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).

A Randomized, Placebo Controlled Study to Determine the Effect of Two Dose Schedules of R1507 or Placebo, Both in Combination With Erlotinib (Tarceva®), on Progression-free Survival in Patients With Advanced Non-small Cell Lung Cancer With Disease Progression After First or Second Line Chemotherapy

Sponsor: Hoffmann-La Roche

Conditions Non-Squamous Non-Small Cell Lung Cancer

Interventions Placebo RG1507 erlotinib [Tarceva]

Updated 9 times since 2017 Last updated: Dec 5, 2020 Started: Nov 10, 2008 Primary completion: Jun 25, 2010 Completion: Jun 25, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was terminated due to the termination of the clinical development program.

Other terminated trials from Hoffmann-La Roche

See all terminations from Hoffmann-La Roche

Other Non-Squamous Non-Small Cell Lung Cancer trials with similar outcome

Browse all Non-Squamous Non-Small Cell Lung Cancer trials

This PHASE2 trial investigates Non-Squamous Non-Small Cell Lung Cancer and is currently terminated or withdrawn. Hoffmann-La Roche leads this study, which shows 9 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE2
Feb 2021 — Dec 2021 [monthly]

Terminated PHASE2

Status: Completed → Terminated

▶ Show 4 earlier versions

Jan 2021 — Feb 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche

Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Atlanta, United States , Bad Berka, Germany , Barcelona, Spain , Berlin, Germany , Beverly Hills, United States , Bilbao, Spain , Boston, United States , Brussels, Belgium , Charleroi, Belgium and 43 more locations